Can chronic caffeine exposure increase adenosine A1 receptor reserve and seizure threshold? A testable hypothesis

This is a hypothesis and in-silico design paper. No animals were used, no experimental data are reported, and nothing in it supports any change in caffeine consumption by anyone. Acutely, caffeine is proconvulsant. Adenosine acting at A1 receptors helps terminate seizures. Caffeine blocks those receptors and acutely lowers seizure threshold, yet long-term caffeine in rodents has been reported to increase A1R binding and reduce chemoconvulsant susceptibility. Whether that adaptation survives clearance of caffeine and its active metabolites is unresolved, and the closest in vivo test — a rat PET study — found no persistent change in A1R availability. We set out three competing hypotheses (adaptation, rebound, no lasting change), a three-group mouse design that discriminates them, and a Monte Carlo analysis used for design planning only. Under the model's assumed adaptation parameters, continuity of exposure rather than cumulative dose is the critical variable, and detectability rests chiefly on how fast adaptation reverses. Design-regime result. Sweeping the two assumptions that matter jointly — the reversal time constant and the fraction of a receptor gain reaching threshold — the proposed design is adequately powered over only about 13% of that plane. At the base-case decay of 7 days the transmission fraction must exceed 0.75; at full transmission the decay constant must exceed 2.0 days; and in the corner resembling the rat PET result power is 0.40. The experiment is informative about a specific and not especially large region of mechanism-space, which is worth stating before animals are used. Eight falsification criteria are specified, together with an explicit account of how the proposal could cause harm — principally self-experimentation, withdrawal-provoked seizures, interaction with existing antiseizure therapy, and the animal cost of running an underpowered study.